ClinVar Miner

Submissions for variant NM_014362.4(HIBCH):c.365A>G (p.Tyr122Cys) (rs121918329)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000224374 SCV000281100 pathogenic not provided 2015-09-17 criteria provided, single submitter clinical testing
GeneDx RCV000224374 SCV000491308 pathogenic not provided 2018-06-06 criteria provided, single submitter clinical testing The Y122C variant in the HIBCH gene has been reported previously in the compound heterozygous state with a splicing variant in a patient with 3-hydroxyisobutyryl-CoA hydrolase deficiency who exhibited hypotonia, poor feeding, developmental delay and regression, ketoacidosis, and basal ganglia abnormalities (Loupatty et al., 2007). The Y122C variant is in 15/245850 (0.006%) alleles in large population cohorts, with no homozygotes observed (Lek et al., 2016). The Y122C variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. Functional studies indicate that Y122C demonstrates normal protein expression with reduced enzyme activity (Loupatty et al., 2007). We interpret Y122C as a pathogenic variant.
Ambry Genetics RCV000623332 SCV000741820 likely pathogenic Inborn genetic diseases 2019-02-08 criteria provided, single submitter clinical testing
SIB Swiss Institute of Bioinformatics RCV000001204 SCV000883163 likely pathogenic Beta-hydroxyisobutyryl-CoA deacylase deficiency 2018-10-15 criteria provided, single submitter curation This variant is interpreted as Likely Pathogenic, for 3-hydroxyisobutryl-CoA hydrolase deficiency, autosomal recessive. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PS3-Moderate => PS3 downgraded in strength to Moderate. PM3-Supporting => PM3 downgraded in strength to Supporting.
Elsea Laboratory,Baylor College of Medicine RCV000001204 SCV001424227 uncertain significance Beta-hydroxyisobutyryl-CoA deacylase deficiency 2020-04-01 criteria provided, single submitter clinical testing
Baylor Genetics RCV000001204 SCV001525528 pathogenic Beta-hydroxyisobutyryl-CoA deacylase deficiency 2019-03-21 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
OMIM RCV000001204 SCV000021354 pathogenic Beta-hydroxyisobutyryl-CoA deacylase deficiency 2007-01-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.